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Abstract
Background: Centrosome aberrations can cause genomic instability and correlate with malignant progression in 
common human malignancies such as breast and prostate cancer. Deregulation of cyclin/cyclin-dependent kinase 2 
(CDK2) activity has previously been shown to be critically involved in centrosome overduplication. We therefore test 
here whether small molecule CDK inhibitors derived from the bis-indole indirubin can be used to suppress centrosome 
aberrations as a novel approach to chemoprevention of malignant progression.
Results: As expected, we found that the CDK inhibitor indirubin-3'-oxime (IO) suppresses centrosome amplification in 
breast cancer cells. However, we made the unexpected discovery that indirubin-derived compounds that have been 
chemically modified to be inactive as kinase inhibitors such as 1-methyl-indirubin-3'-oxime (MeIO) still significantly 
reduced centrosome amplification. All indirubins used in the present study are potent agonists of the aryl hydrocarbon 
receptor (AhR), which is known for its important role in the cellular metabolism of xenobiotics. To corroborate our 
results, we first show that the coincidence of nuclear AhR overexpression, reflecting a constitutive activation, and 
numerical centrosome aberrations correlates significantly with malignancy in mammary tissue specimens. Remarkably, 
a considerable proportion (72.7%) of benign mammary tissue samples scored also positive for nuclear AhR 
overexpression. We furthermore provide evidence that continued expression of endogenous AhR is critical to promote 
centriole overduplication induced by cyclin E and that AhR and cyclin E may function in the same pathway. 
Overexpression of the AhR in the absence of exogenous ligands was found to rapidly disrupt centriole duplication 
control. Nonetheless, the AhR agonists IO and MeIO were still found to significantly reduce centriole overduplication 
stimulated by ectopic AhR expression.
Conclusions: Our results indicate that continued expression of endogenous AhR promotes centrosome amplification 
in breast cancer cells in a pathway that involves cyclin E. AhR agonists such as indirubins inhibit centrosome 
amplification even when stimulated by ectopic expression of the AhR suggesting that these compounds are 
potentially useful for the chemoprevention of centrosome-mediated cell division errors and malignant progression in 
neoplasms in which the AhR is overexpressed. Future studies are warranted to determine whether individuals in which 
nuclear AhR overexpression is detected in benign mammary tissue are at a higher risk for developing pre-cancerous or 
cancerous breast lesions.
Background
The aryl hydrocarbon receptor (AhR) is a cytoplasmic,
ligand-activated transcription factor that mediates the
toxicity of halogenated or polycyclic aromatic hydrocar-
bons including dioxins or benzo[a]pyrene [1]. Long-term
exposure to such xenobiotics has been implicated in an
increased risk for common human malignancies includ-
ing breast and prostate cancer [2,3]. Both cancer types
frequently show an aberrant AhR expression [2,4], how-
ever, there is compelling evidence that the AhR can pro-
mote cancer formation independent of the presence of
exogenous ligands [2,5,6]. Support for this notion stems
mainly from studies in breast cancer.
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The AhR was found to be overexpressed in primary
breast cancers and mammary tumor cell lines in the
absence of detectable xenobiotics [2] and there is con-
vincing evidence for a critical role of endogenous AhR in
proliferation control in tumor cells [1]. Inhibition of the
AhR was found to be associated with slow growth and
downregulation of cyclin and CDK2 expression [7] sug-
gesting that its continued expression is important for cell
cycle progression [1]. The tumorigenic function of the
AhR is underscored by the fact that constitutively active
AhR induces stomach tumors in rodents [8]. Paradoxi-
cally, acute activation of the AhR by 2,3,7,8-tetrachlorod-
ibenzo-p-dioxin (TCDD; dioxin) inhibits tumor cell
proliferation through mechanisms that involve upregula-
tion of the CDK inhibitor p27Kip1, binding of the pRB
tumor suppressor, suppression of E2F-mediated tran-
scription as well as inhibition of hormone signaling [9-
11]. Taken together, these results highlight that altered
expression of endogenous AhR that is not activated by
exogenous ligand has, in general, pro-proliferative and
tumor-promoting properties, whereas exogenously acti-
vated AhR can have anti-proliferative activities.
Disruption of cell cycle control and increased prolifera-
tion is a common finding in breast cancer [12]. A number
of studies have shown that aberrant cell proliferation pro-
motes not only the production of increased numbers of
daughter cells but at the same time increases the risk of
genomic instability, another hallmark of most epithelial
malignancies [13,14]. A link between deregulated cell
cycle control and genomic instability is provided by the
centrosome duplication cycle [15]. Centrosomes function
as major microtubule organizing centers in most mam-
malian cells during interphase and mitosis [16]. Tumor
cells frequently show abnormal centrosome numbers that
can increase the risk for cell division errors, chromosome
missegregation and aneuploidy [17,18]. Besides promot-
ing polarity disturbances, it has recently been reported
that extra centrosome can lead to merotelic microtubule
attachment to kinetochores thereby causing chromosome
segregation defects [19]. In breast cancer, centrosome
aberrations have been detected in pre-invasive ductal
lesions and independently of inactivation of p53 [20-22].
The latter finding is critical because it underscores that
centrosome aberrations may directly cause cell division
errors in breast cancer and are not merely a consequence
of genomic instability associated with p53 loss or unre-
lated cellular defects [23,24]. It furthermore suggests that
centrosome aberrations may directly arise from disrup-
tion of centrosome duplication control. A number of
genes frequently altered in breast cancer including
BRCA1 [25] as well as estrogen signaling [26,27] have
been implicated in centrosome amplification.
Given the fact that centrosome aberrations arise early
during malignant progression as shown by Lingle and co-
workers [20] and have a potentially detrimental impact
on genome integrity, it has been proposed that the cen-
trosome duplication process may be a target to prevent
progressive chromosomal instability in early stage lesions
and hence progression to invasive cancer [28].
Deregulation of cyclin E/CDK2, an early and frequent
finding in breast cancer [29], has recently been shown to
cause an aberrant recruitment of the centrosomal protein
kinase PLK4 to centrioles thereby promoting centriole
and centrosome overduplication [30]. Given the crucial
role of CDK2 in centriole amplification and the high fre-
quency of its deregulation in early stage breast cancer
[12,29], we asked here whether targeting CDK2 can pre-
vent centrosome aberrations in breast cancer cells.
Using the indirubin-derived CDK inhibitor indirubin-
3'-oxime (IO) and its counterpart 1-methyl-indirubin-3'-
oxime (MeIO), which has been chemically modified to be
inactive as a kinase inhibitor [11], we unexpectedly dis-
covered that both kinase-active and kinase-inactive com-
pounds effectively inhibited centrosome overduplication
in breast cancer cell lines. Importantly, IO, MeIO and a
number of other indirubins used in our experiments are
potent AhR agonists [31-33]. In an effort to further eluci-
date a connection between AhR and centrosome aberra-
tions, we found that the combined presence of nuclear
AhR overexpression and numerical centrosome aberra-
tions correlated significantly with malignancy in mam-
m a r y  t i s s u e  s p e c i m e n s .  S u r p r i s i n g l y ,  w e  f o u n d  t h a t  a
considerable proportion of benign mammary tissue sam-
ples scored positive for nuclear AhR overexpression. In
vitro experiments showed that continued expression of
endogenous AhR is critical to promote centriole overdu-
plication induced by cyclin E and that the AhR and cyclin
E may function in the same pathway. Furthermore, over-
expression of the AhR in the absence of exogenous ligand
was found to rapidly disrupt centriole duplication con-
trol. Nonetheless, AhR agonists including IO and MeIO
were still found to significantly reduce centriole overdu-
plication stimulated by ectopic AhR expression.
Collectively, our results provide evidence for a novel
role of the AhR in centriole duplication and suggest that
AhR-agonistic indirubins are potentially useful to prevent
centrosome-mediated chromosome instability and malig-
nant progression even in lesions that overexpress the
AhR. Whether individuals with nuclear AhR overexpres-
sion are at a higher risk for the formation of pre-cancer-
ous and cancerous lesions will be the subject of future
studies.
Methods
Cell culture, transfections and inhibitor treatments
Human HCC1806 and MCF-7 mammary tumor cell lines
w e r e  o b t a i n e d  f r o m  A T C C  a n d  m a i n t a i n e d  a s  r e c o m -
mended by the vendor. MCF-7 cells were stably trans-Korzeniewski et al. Molecular Cancer 2010, 9:153
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fected with either pCMV-based plasmids encoding cyclin
E (kindly provided by Philip Hinds, Tufts University, Bos-
ton, MA) [34] or empty vector (neo) or pEGFP-centrin-1-
GFP (kindly provided by Michel Bornens, Institut Curie,
Paris, France) [35]. For transient overexpression, a
pcDNA-based human AhR plasmid (kindly provided by
David Sherr, Boston University, Boston, MA) [36] was
used. Indirubin-3'-oxime (IO), 1-methyl-indirubin-3'-
oxime (MeIO), 6-bromo-indirubin-3'-oxime (BIO), 1-
methyl-6-bromo-indirubin-3'-oxime (MeBIO) and 6-
bromo-indirubin-3'-acetoxime (BIA) (all compounds
were generously provided by Laurent Meijer, Station
Biologique, Roscoff, France) were dissolved in DMSO and
used at a 1 μM concentration for 24 h. DMSO was
included as solvent control in all experiments.
Immunological methods
Immunoblot analyses of whole cell protein extracts were
performed as previously described [37]. For immunofluo-
rescence microscopic analysis of AhR expression and
centrosome numbers, a breast multitissue array (BR1003;
Biomax US) was used. Sections were processed as previ-
ously described [38] and incubated with an anti-AhR
antibody (Santa Cruz) at a 1:100 dilution or an anti-γ-
tubulin antibody (Sigma) at a 1:500 dilution for at least
two days at 4°C followed by FITC-conjugated secondary
antibodies (Jackson Immunoresearch). Immunofluores-
cence staining for centrin (antibody kindly provided by
Jeffrey Salisbury, Mayo Clinic, Rochester, MN) was per-
formed as previously described [37]. Nuclei were stained
with DAPI. Sections were analyzed using an Olympus
AX70 epifluorescence microscope. For quantification of
AhR staining, tissue cores were scored positive when at
least a single breast epithelial or tumor cell with nuclear
AhR expression was detected (see Additional File 1). For
quantification of centrosome abnormalities, three sec-
tions of the same multi-tissue array were stained inde-
pendently for γ-tubulin and the proportion of cells with
centrosome aberrations (more than two centrosome per
cell) was quantified (see Additional File 1). A core that
contained at least one cell with abnormal centrosome
numbers in one of the three independent experiments
scored as positive. All tissue cores with insufficient stain-
ing quality were excluded from our analysis ("not assess-
able", NA in Additional File 1).
Small-interfering RNA (siRNA)
Synthetic RNA duplexes to reduce AhR expression and
control RNA duplexes were obtained commercially
(Ambion) and used according to manufacturer's protocol.
Statistical Analysis
Student's two-tailed t test for independent samples was
used wherever applicable. To assess the correlation
between nuclear AhR overexpression, numerical cen-
trosome abnormalities or a combination of both, respec-
tively, with malignancy, benign (normal and hyperplasia)
and malignant (dysplasia and cancer) samples were
s c o r e d  a s  e i t h e r  p o s i t i v e  o r  n e g a t i v e  f o r  e a c h  o r  b o t h
markers (columns two and six of Additional File 1). See
Immunological Methods for more details of the scoring
method. 2 × 2 contingency tables were created followed
by a two-tailed Fisher exact probability test.
Results
Indirubins inhibit centriole overduplication in breast 
cancer cells
Given the crucial role of cyclin/CDK2 complexes in pro-
moting centriole overduplication [39], we sought to
determine whether indirubin-derived small molecule
CDK inhibitors can suppress centrosome amplification in
breast cancer cells.
Triple-negative (estrogen receptor-, progesterone
receptor, HER2-negative) HCC1806 breast cancer cells
were treated with indirubin-3'-oxime (IO) in comparison
to kinase-inactive 1-methyl-indirubin-3'-oxime (MeIO)
and several indirubin analogues (Table 1), all at a 1 μM
concentration for 24 h, and stained for centrin to visual-
ize individual centrioles (Fig. 1A). In all of our experi-
ments, bi- or multinucleated cells were excluded from the
analysis since they are commonly associated with centri-
ole accumulation in contrast to centriole overduplication
[40]. As expected [28], IO, which effectively inhibits
CDK2, CDK1 and GSK-3β [41], was found to lead to a
significant 2.5-fold reduction of the proportion of cells
with abnormal centrosome numbers from 10.6% in
DMSO-treated controls to 4.2% in cells treated with IO (p
≤ 0.0001; Fig. 1B). Surprisingly, however, the kinase-inac-
tive counterpart of IO, MeIO, also caused a significant
2.9-fold reduction of cells with centrosome aberrations to
3.6% (p ≤ 0.0001; Fig. 1B). Similar results were obtained
when we treated HCC1806 cells with 6-bromo-indirubin-
3'-oxime (BIO; 2.8%, p ≤ 0.0001), the kinase-inactive
compound 1-methyl-6-bromo-indirubin-3'-oxime
(MeBIO; 2.8%, p ≤ 0.0001) or 6-bromo-indirubin-3'-ace-
toxime (BIA; 5.2%, p ≤ 0.001), which was the least effec-
tive indirubin analogue in terms of reduction of centriole
overduplication (Fig. 1B).
We next manipulated MCF-7 breast cancer cells to sta-
bly overexpress cyclin E in order to hyperstimulate cen-
triole overduplication. When MCF-7/cyclin E cells were
treated with 1 μM IO or MeIO for 24 h, a significant 2.7-
fold reduction of the proportion of cells with aberrant
centriole numbers from 25.2% in DMSO-treated controls
to 9.5% in IO-treated cells (p ≤ 0.01) and 13.3% in MeIO-
treated cells (1.9-fold; p ≤ 0.05) was detected. A decrease
of the proportion of cells with aberrant centriole numbersKorzeniewski et al. Molecular Cancer 2010, 9:153
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was also detected when MCF-7/cyclin E cells were
treated with BIO (14.1%; p ≤ 0.05), kinase-inactive
MeBIO (12.1%; p ≤ 0.005) or BIA (8.3%; p ≤ 0.0001). A
moderate decrease of cells with numerical centriole aber-
rations was also detected in control MCF-7 cells stably
expressing empty vector (MCF-7/neo) treated with IO
(5.8%; p ≤ 0.05), MeIO (6.3%; p ≤ 0.05), BIO (5.8%; p >
0.05), MeBIO (5.7%; p ≤ 0.05) or BIA (5.8%; p ≤ 0.01) in
comparison to DMSO (8.8%).
The reduction of cells with centriole aberrations follow-
ing treatment with kinase-inactive MeIO or MeBIO was
unexpected. MeIO as well as all other indirubins tested
have previously been reported to exert kinase-indepen-
dent activities through binding and activation of the AhR
(Table 1). Both cell types used, HCC1806 and MCF-7
cells showed a robust protein expression of the AhR by
immunoblot analysis (not shown). Since the AhR has not
been implicated in centriole duplication control before,
we sought to determine the biological relevance of this
association and analyzed the expression of the AhR in
correlation to centrosome abnormalities in primary
breast tissue samples.
AhR overexpression and centrosome aberrations correlate 
with malignancy in mammary tissue specimens
Expression of the AhR was analyzed in non-malignant
and malignant breast tissue specimens using a multi-tis-
sue array. A total of six normal breast tissue samples, 16
hyperplastic tissue samples, 13 dysplastic tissue samples
and 19 cancerous tissue samples were analyzed (Addi-
tional File 1). We detected nuclear overexpression of the
AhR (Fig. 2) in four of six normal samples (66.7%), 12 of
16 hyperplastic samples (75%), nine of 13 dysplastic sam-
ples (69.2%) and 17 of 19 breast cancer samples (89.5%,
see Methods for details of scoring procedure). These
results show that the AhR is overexpressed in a subset of
benign and malignant breast tissue samples and, further-
more, that its expression tends to increase with malignant
progression.
We then analyzed adjacent sections of the same multi-
tissue array for the presence of supernumerary cen-
trosomes (Fig. 3). Abnormal centrosome numbers (more
than two per cell) were assessed following immunofluo-
rescence microscopy for γ-tubulin, a marker of the peri-
centriolar material. Most cells with aberrant centrosome
numbers contained a group of three centrosomes (see
Fig. 3, bottom two panels). At least one cell with abnor-
mal centrosome numbers was detected in two of six nor-
mal breast tissue samples (33.3%), nine of 16 hyperplastic
lesions (56.3%), 12 of 13 dysplastic lesions (92.3%) and 18
of 19 cancerous lesions (94.7%). The mean percentage of
cells with numerical centrosome aberrations was 0.5% in
normal controls. 2.9% in hyperplastic samples, 4.6% in
dysplasias and 9.6% in invasive carcinomas (see Addi-
tional File 1).
We next asked whether the presence of nuclear AhR
overexpression or centrosome aberrations correlates with
malignancy. Whereas we found a statistically significant
correlation between numerical centrosome aberrations
and malignancy (dysplasia and cancer, p ≤ 0.0005, two-
tailed Fisher exact probability test), no such correlation
was detected for AhR overexpression alone. However, the
coincidence of nuclear AhR overexpression and abnormal
centrosome aberrations in a given tissue sample was
found to correlate significantly with malignancy (p ≤
0.005, two-tailed Fisher exact probability test).
Taken together, these results suggest a positive correla-
tion between nuclear AhR overexpression, centrosome
amplification and malignancy in mammary tissue sam-
ples. They also provide evidence for a surprisingly high
level of nuclear AhR overexpression in normal and hyper-
plastic breast tissue specimens and hence support the
n o t i o n  t h a t  t h e  A h R  m a y  p l a y  a  r o l e  i n  e a r l y  s t e p s  o f
breast carcinogenesis.
AhR is necessary to promote centriole overduplication in 
breast cancer cell lines
To further corroborate a correlation between the AhR
and centrosome amplification, we next examined centri-
Table 1: Activity spectrum of indirubins
Compound CDK2 inhibition CDK1 inhibition GSK-3β inhibition AhR activation
Indirubin-3'-oxime (IO) ++a ++b +++b ++b
1-Methyl-indirubin-3'-oxime (MeIO) inactiveb -b -b ++b
6-Bromo-indirubin-3'-oxime (BIO) ++a ++b +++b ++b
1-Methyl-6-bromo-indirubin-3'-oxime 
(MeBIO)
inactiveb -b - +++b
6-Bromo-indirubin-3'-acetoxime (BIA) +a -b +++b ++b
IC50 (kinases, μM), EC50 (AhR, μM): <0.1 = +++; <1 = ++; 1-10,000 = +; >10,000 = -
aData from Meijer et al., Chem. Biol. 2003; 10:1255-1266.
bData from Knockaert et al., Oncogene 2004; 23:4400-4412.Korzeniewski et al. Molecular Cancer 2010, 9:153
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ole overduplication in HCC1806 and MCF-7 cells follow-
ing siRNA-mediated AhR depletion (Fig. 4). Knock-down
of the AhR by siRNA (Fig. 4A) was associated with a sig-
nificant 2.1-fold reduction of the proportion of HCC1806
Figure 1 Indirubins inhibit centriole overduplication in breast 
cancer cell lines. (A) Immunofluorescence microscopic analysis of 
HCC1806 breast cancer cells for centrin to visualize normal centrioles 
(top panels) in contrast to centriole overduplication (bottom panels). 
Nuclei stained with DAPI. Scale bar indicates 10 μm. (B, C) Quantifica-
tion of the proportion of HCC1806 or MCF-7 cells manipulated to sta-
bly express empty vector (MCF-7/neo) or cyclin E (MCF-7/cyclin E) with 
aberrant centriole numbers (>4 per cell) after treatment with 0.1% 
DMSO as solvent control or 1 μM indirubin-3'-oxime (IO), 1 μM 1-meth-
yl-indirubin-3'-oxime (MeIO), 1 μM 6-bromo-indirubin-3'-oxime (BIO), 1 
μM 1-methyl-6-bromo-indirubin-3'-oxime (MeBIO) or 1 μM 6-bromo-
indirubin-3'-acetoxime (BIA) for 24 h. Each bar represents mean and 
standard error of at least three independent experiments with a mini-
mum of 50 cells counted per experiment. Only mononucleated cells 
were assessed for centriole aberrations to exclude polyploid or other-
wise altered cells.
Figure 2 The AhR is overexpressed in non-malignant and malig-
nant breast tissue. Examples of an immunofluorescence microscopic 
analysis of non-malignant and malignant breast tissue specimens for 
nuclear overexpression of the AhR. Note the nuclear staining in the hy-
perplastic tissue specimen (second row from the top) as well as in the 
dysplasia and carcinoma. Nuclei stained with DAPI. Scale bar indicates 
100 μm.
Figure 3 Centrosome aberrations in breast tissue. Examples of an 
immunofluorescence microscopic analysis of non-malignant and ma-
lignant breast tissue specimens for the centrosome marker γ-tubulin. 
Note the presence of extra centrosomes in the dysplastic and cancer-
ous tissue specimens. Arrows in inset point to centrosomes. Nuclei 
stained with DAPI. Scale bar indicates 50 μm.Korzeniewski et al. Molecular Cancer 2010, 9:153
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Figure 4 Knock-down of the AhR reduces centriole aberrations in breast cancer cell lines. (A, B) Immunoblot analysis of HCC1806 cells for AhR 
expression after transient transfection of cells with siRNA targeting the AhR or control siRNA duplexes. Immunoblot for Actin is shown to demonstrate 
protein loading (A). Quantification of the proportion of HCC1806 cells with aberrant centriole numbers following transfection with siRNA targeting 
the AhR or control siRNA. Each bar represents mean and standard error of at least three independent experiments with a minimum of 50 cells counted 
per experiment (B). (C, D) Immunoblot analysis of MCF-7/neo and MCF-7/cyclin E cells for AhR expression after transient transfection of cells with siRNA 
targeting the AhR or control siRNA duplexes. Immunoblot for actin is shown to demonstrate protein loading (C). Quantification of the proportion of 
cells with aberrant centriole numbers following transfection with siRNA targeting the AhR or control siRNA. Each bar represents mean and standard 
error of at least three independent experiments with a minimum of 50 cells counted per experiment (D). (E) Immunoblot analysis of MCF-7/neo and 
MCF-7/cyclin E cells following transient transfection (72 h) with either control siRNA (siControl) or siRNA targeting the AhR (siAhR). Immunoblots for 
AhR, cyclin E, cyclin A, p27Kip1 and actin are shown. (F) Quantification of the proportion of MCF-7/neo cells (open bars) and MCF-7/cyclin E cells (black 
bars) with n > 4 centrioles following transient transfection with either control siRNA (siControl) or siRNA duplexes targeting CDK2 (siCDK2), cyclin E 
(siCyclin E), AhR (siAhR), CDK2 and AhR (siCDK2/siAhR) or cyclin E and AhR (siCyclin E/siAhR). Each bar represents mean and stardard error of two in-
dependent experiments each with triple quantification of at least 50 cells.Korzeniewski et al. Molecular Cancer 2010, 9:153
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cells with aberrant centriole numbers from 14.6% in con-
trols to 6.8% in AhR-depleted cells (p ≤ 0.05; Fig. 4B).
Knock-down of the AhR in MCF-7/cyclin E cells (Fig.
4C) was likewise found to cause a statistically significant
2.2-fold reduction of the proportion of cells with aberrant
centriole numbers from 14.7% in control siRNA-trans-
fected MCF-7/cyclin E cells to 6.6% in AhR-depleted
MCF-7/cyclin E cells (p ≤ 0.05; Fig. 4D). No significant
change was detected in MCF-7/neo controls transfected
with AhR siRNA in comparison to control siRNA (p >
0.05).
The finding that AhR knock-down in MCF-7/cyclin E
cells reduced centriole overduplication to the baseline
levels detected in MCF-7/neo control cells, but not
below, raises the possibility that cyclin E and AhR may
function in the same pathway . T o explore this idea, we
performed an immunoblot analysis of control siRNA- or
AhR siRNA-transfected MCF-7/neo and MCF-7/cyclin E
cells (Fig. 4E). We detected an increase of baseline AhR
protein expression in MCF-7 overexpressing cyclin E (see
siControl lane; Fig. 4E). On the other hand, knock-down
of AhR expression led to a reduction of cyclin E protein
expression in MCF-7/cyclin E cells (see siAhR lane; Fig.
4E). A modest decrease in cyclin A protein expression
was seen in MCF-7/neo cells. MCF-7/cyclin E cells
showed increased baseline levels of p27Kip1 in comparison
to MCF-7/neo cells but no major changes following AhR
depletion were found. These results suggest a positive
feedback mechanism between cyclin E and AhR and are
in line with previous reports showing a pro-proliferative
function of endogenous AhR in contrast to growth-sup-
pressive activities of exogenously activated AhR.
To further support the notion that cyclin E and AhR
may function in the same pathway, we performed an
additional series of siRNA experiments (Fig. 4F). SiRNA-
mediated knock-down of either CDK2, cyclin E or AhR
alone or in combination was performed in MCF-7/neo or
MCF-7/cyclin E cells. Knock-down of CDK2 alone led to
a statistically significant 2.3-fold reduction of the propor-
tion of cells with aberrant centriole numbers from 21.3%
in control siRNA-transfected MCF-7/cyclin E cells to
9.3% (p ≤ 0.005). Knock-down of cyclin E alone as well as
AhR alone also caused a statistically significant 3.2-fold
and 4.1-fold reduction, respectively, to 6.7% (p ≤ 0.001)
and 5.2% (p ≤ 0.005) in MCF-7/cyclin E cells. Co-deple-
tion of CDK2 and AhR led to a statistically significant 2.9-
fold reduction of the proportion of cells with aberrant
centriole numbers to 7.3% (p ≤ 0.005) whereas co-deple-
tion of cyclin E and AhR caused a statistically significant
4.5-fold reduction to 4.7% (p ≤ 0.001) in MCF-7/cyclin E
cells.
Collectively, these findings demonstrate that continued
endogenous AhR expression is critical for centriole over-
duplication and furthermore suggest that cyclin E and
endogenous AhR may function in the same pathway.
Overexpression of the AhR causes centriole 
overduplication
To directly test whether overexpression of the AhR can
disrupt centriole duplication control in breast cancers
cells, MCF-7 cells manipulated to stably express centrin-
GFP to visualize individual centrioles were transiently
transfected with full-length human AhR (Fig. 5A). Ecto-
pic expression of the AhR was found to stimulate aber-
rant centriole duplication with a statistically significant
1.8-fold increase from 15.2% in empty vector controls to
26.8% in AhR-transfected cells (p ≤ 0.05; Fig. 5B). A par-
ticularly striking phenotype that was detected in a pro-
portion of MCF-7 cells was the formation of multiple
daughter centrioles at single maternal centrioles follow-
ing AhR overexpression (Fig. 5A; right panel). This phe-
notype is also referred to as centriole multiplication and
indicates a genuine disruption of centriole duplication
control.
We next tested whether cells in which centriole overdu-
plication was induced by overexpression of the AhR
would respond to the inhibitory effects of IO and MeIO.
MCF-7/centrin-GFP cells were transiently transfected
w i t h  e m p t y  v e c t o r  o r  a n  A h R - e n c o d i n g  p l a s m i d  a n d
treated with 1 μM IO or MeIO after 24 h for an additional
24 h (Fig. 5C). As expected, ectopic expression of the AhR
led to a statistically significant 2.6-fold increase of cells
with supernumerary centrioles from 7.3% in controls to
18.7% (p ≤ 0.001). Both, IO and MeIO caused a statisti-
cally significant reduction of cells with aberrant centriole
numbers in AhR-transfected cells to 12.7% in IO-treated
cells (p ≤ 0.05) and 12% in MeIO-treated cells (p ≤ 0.05).
These results further support a role of the AhR in pro-
moting centriole overduplication in breast cancer cells
and underscore that AhR agonists such as IO retain their
ability to inhibit centriole overduplication even in cells
with AhR overexpression.
Discussion
Overexpression of the AhR has been detected in a num-
ber of cancerous and pre-cancerous lesions including
breast and prostate cancer [2,4]. I t is believed that the
nuclear localization of the AhR in such lesions indicates
its constitutive activation, although the precise molecular
mechanisms leading to such activation remain elusive.
Endogenous AhR that is not activated by exogenous
ligand has, in general, pro-proliferative and tumor-pro-
moting properties [1,8]. We report here a novel role of
the AhR in centrosome duplication control. Given that
supernumerary centrioles can cause cell division errors
and chromosomal instability, this finding provides a
potential link between the AhR and malignant progres-Korzeniewski et al. Molecular Cancer 2010, 9:153
http://www.molecular-cancer.com/content/9/1/153
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Figure 5 Overexpression of the AhR stimulates centriole overduplication that can be reverted by indirubins. (A) Fluorescence microscopic 
analysis of MCF-7 cells stably expressing centrin-GFP to visualize individual centrioles after transient transfection of cells with AhR or empty vector 
(control). Note the presence of two daughter centrioles at single maternal centrioles indicating aberrant daughter centriole synthesis (right panel). 
Arrows in right inset point to extra centrioles in an AhR-transfected cell. (B) Quantification of the proportion of MCF-7/centrin-GFP cells with aberrant 
centriole numbers following transfection with AhR or empty vector (control). Each bar represents mean and standard error of at least three indepen-
dent experiments with a minimum of 50 cells counted per experiment. (C) Quantification of the proportion of MCF-7/centrin-GFP cells with n > 4 
centrioles following transient transfection with either empty vector control (open bars) or AhR (black bars) and treatment with 0.1% DMSO, 1 μM IO 
or 1 μM MeIO starting 24 h after transfection of cells for an additional 24 h. Each bar represents mean and standard error of at least triple quantification 
of at least 50 cells.Korzeniewski et al. Molecular Cancer 2010, 9:153
http://www.molecular-cancer.com/content/9/1/153
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sion. Remarkably, overexpression of the AhR can lead to
centriole multiplication, a novel pathway of centriole
overduplication that has only been found in the context
of a few stimuli so far such as PLK4 overexpression or the
human papillomavirus type 16 E7 oncoprotein (HPV-16
E7) [42,43].
Continued AhR expression was found to be necessary
to promote centriole overduplication in HCC1806 breast
cancer cells as well as MCF-7 cells stably expression
cyclin E to hyperstimulate centriole overduplication.
Ectopic cyclin E expression was associated with an upreg-
ulation of AhR protein expression while depletion of AhR
in MCF-7 cells stably expressing cyclin E caused a
decreased of cyclin E protein levels. Together with the
finding that knock-down of either cyclin E or AhR has
basically identical effects in terms of reduction of centri-
ole overduplication, these results suggest that cyclin E
and AhR may function in the same pathway to promote
centriole overduplication. Since overexpression of cyclin
E/CDK2 alone is necessary but not sufficient to induce
centriole multiplication [30], it is likely that the AhR also
affects additional components of the molecular circuitry
that normally limits centriole biogenesis.
The AhR belongs to the bHLH family of transcription
factors and two other members of this family, c-MYC and
ID1, have been identified to also stimulate centrosome
overduplication [30,44]. ID1 has been shown to interfere
with a component of the ubiquitin-proteasome machin-
ery to promote centrosome amplification [45]. Although
the function of the AhR as part of a CUL4B-based E3
ubiquitin ligase [10,46] has not been explored in the
absence of AhR ligand, it is possible that this activity is
involved in centrosome overduplication, potentially
through the degradation of a protein that normally
restrains centriole biogenesis [42]. This notion is under-
scored by previous results showing that protein degrada-
tion plays a critical role in the regulation of daughter
centriole biogenesis, in particular centriole multiplication
[42], which we detected in a proportion of cells following
ectopic expression of the AhR (Fig. 5). Although it
remains to be experimentally confirmed, it is likely that
the disruption of centriole duplication control by the AhR
promotes centrosome-mediated cell division errors,
chromosomal instability and malignant progression.
It is noteworthy that centrosome aberrations and mul-
tipolar mitoses are frequent findings in pre-cancerous
lesions of the mammary gland and the prostate, both
tumor entities in which aberrant AhR expression has
been suggested to play a pathogenic role [2,4]. Our own
results confirm and extend these results by showing that
the coincidence of nuclear AhR overexpression and
numerical centrosome aberrations correlates significantly
with malignancy in mammary tissue samples. Surpris-
ingly, aberrant AhR expression was detected not only in
tumor samples but also in a considerable proportion of
normal and hyperplastic mammary gland tissue speci-
mens. Whether this reflects a role of endogenous AhR in
normal cellular functions or a widespread pathological
activation of this receptor by one or more ubiquitous xen-
obiotics remains to be determined. The finding that cellu-
lar alterations that are believed to be characteristic of
malignancy can be detected in healthy individuals is not
unprecedented. For example, hypermethylation of the
p16INK4A promoter has been reported in about 30% of tis-
sue specimens from healthy women [47]. In any case, it
will be important to investigate whether individuals with
nuclear AhR overexpression in benign mammary tissue
are at a higher risk to develop breast cancer.
There is an ongoing discussion whether the AhR can or
should be exploited as a pharmacological target [48].
Results shown here provide compelling evidence that
analogues of the bis-indole indirubin, which are known
AhR agonists [31-33], can suppress centrosome overdu-
plication in breast cancer cell lines in vitro. This activity
was even detectable when centriole amplification was
induced by AhR overexpression. We did not detect a sig-
nificant inhibition of cell proliferation in cells treated
with indirubins (data not shown), which is in line with
our previous finding that centrosome overduplication
can be inhibited independently from the cell division
cycle [28]. Nonetheless, the activity spectrum of IO,
which inhibits CDKs and has agonistic functions on the
AhR, may be particularly favorable to target tumor cells.
Since loss of genome stability is a progressive process, it
will be necessary to target genomic instability at an early
stage such as in pre-cancerous lesions. These lesions
already frequently show signs of chromosomal instability
s u c h  a s  c e n t r o s o m e  a b e r r a t i o n s ,  a n e u p l o i d y  o r  D N A
damage [49]. Based on these results, the development of
suitable animal models to test indirubins as chemopre-
vention agents is clearly warranted.
Conclusions
Our results support a role of endogenous AhR in promot-
ing centrosome and centriole amplification in mammary
tumors and breast cancer cell lines. However, AhR ago-
nists such as indirubins were found to effectively sup-
press centriole overduplication even when stimulated by
ectopic AhR expression. Our finding that a significant
proportion of non-neoplastic breast tissue specimens
showed nuclear overexpression of the AhR raises the
question whether these individuals have an increased risk
for centrosome-mediated cell division errors, aneuploidy
and malignant progression. Collectively, these results
provide a framework for future studies to manipulate the
AhR for cancer chemoprevention.Korzeniewski et al. Molecular Cancer 2010, 9:153
http://www.molecular-cancer.com/content/9/1/153
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